Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?

Overview of attention for article published in Frontiers in oncology, September 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 7 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,713 followers.

RT @FrontOncology: New research: Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?: Metastatic urothelial car…

19 Sep 2023

Reply Repost Favourite

New research: Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?: Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate… #oncology https

19 Sep 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.